Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 35

Results For "Navi"

367 News Found

AstraZeneca-Sputnik V combination demonstrates high immunogenicity profile: RDIF
Biotech | August 20, 2021

AstraZeneca-Sputnik V combination demonstrates high immunogenicity profile: RDIF

Preliminary data from the first 20 participants in Azerbaijan show antibodies to the SARS-CoV-2 virus spike protein (S-protein) elicited in 100% of cases


Real world data from Paraguay shows one-shot Sputnik Light vaccine has high safety and efficacy of 93.5 %
Biotech | August 18, 2021

Real world data from Paraguay shows one-shot Sputnik Light vaccine has high safety and efficacy of 93.5 %

Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik


European Commission mandates InferVision AI to monitor Covid-19 variants
Digitisation | August 17, 2021

European Commission mandates InferVision AI to monitor Covid-19 variants

InferVision's AI applications have been developed to quickly and accurately analyse signs of pulmonary infections from regular chest CT images. These images are processed to indicate ground-glass opacity and high tissue density, which are key findings of viral pneumonia caused by the coronavirus


India restricts export of Rapid Antigen Test Kits used to detect Covid 19
Policy | August 16, 2021

India restricts export of Rapid Antigen Test Kits used to detect Covid 19

The notification implies that any export of Rapid Antigen Kit will require a licence or permission from DGFT


Novatek Pharma initiates Phase II study of oral COVID-19 drug
Drug Approval | August 14, 2021

Novatek Pharma initiates Phase II study of oral COVID-19 drug

This therapy may provide the first potential oral treatment for COVID-19, recognizing the global emergency of new SARS-CoV-2 variants


QIAGEN and OncXerna Therapeutics sign licensing and master companion diagnostic agreements
Drug Approval | August 10, 2021

QIAGEN and OncXerna Therapeutics sign licensing and master companion diagnostic agreements

QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab


AIkido updates on use of machine learning in drug development orogram
Digitisation | August 09, 2021

AIkido updates on use of machine learning in drug development orogram

The goal for the project is the identification and optimization of anti-viral compounds.


Bafna Pharma posts Q1FY 21-22 net at Rs. 2.08 Cr
News | August 07, 2021

Bafna Pharma posts Q1FY 21-22 net at Rs. 2.08 Cr

This robust growth has come despite the raging pandemic for most part of the quarter


Novavax signs agreement with European Commission for COVID19 vaccine
Biotech | August 05, 2021

Novavax signs agreement with European Commission for COVID19 vaccine

Deal for 100 million doses with additional 100 million through 2023